Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research.

Efalizumab (78 ng/mL-5 mg/mL) induces a leukocytosis and downregulates LFA-1 expression on T cells in the peripheral blood.
Efalizumab (78 ng/mL-5 mg/mL) downregulates plate-bound, anti-CD3-stimulated proliferation of PBMC.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Efalizumab shows side effects include bacterial sepsis, viral meningitis, invasive fungal disease and progressive multifocal leukoencephalopathy (PML), a brain infection caused by reactivation of latent JC virus infection.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Efalizumab shows side effects include bacterial sepsis, viral meningitis, invasive fungal disease and progressive multifocal leukoencephalopathy (PML), a brain infection caused by reactivation of latent JC virus infection.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S98-104.  [Content Brief]

  . Berger JR, et al. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs. 2009 Nov-Dec;1(6):583-9.  [Content Brief]

  . Koszik F, et al. Efalizumab modulates T cell function both in vivo and in vitro. J Dermatol Sci. 2010 Dec;60(3):159-66.  [Content Brief]